2007
DOI: 10.1016/j.thromres.2006.02.002
|View full text |Cite
|
Sign up to set email alerts
|

The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
8
0

Year Published

2007
2007
2015
2015

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 29 publications
0
8
0
Order By: Relevance
“…This suggests that augmented VCAM-1 expression may reflect inflammation and endothelial dysfunction and hence impairing the regulation of blood pressure. This is because a significant reduction in the cell adhesion molecules expression may indicate a better preservation of endothelial function [55]. Besides, we do believe that the increased VCAM-1 (that is inflammation) may play a role, at least in part, in causing adverse remodelling.…”
Section: Discussionmentioning
confidence: 99%
“…This suggests that augmented VCAM-1 expression may reflect inflammation and endothelial dysfunction and hence impairing the regulation of blood pressure. This is because a significant reduction in the cell adhesion molecules expression may indicate a better preservation of endothelial function [55]. Besides, we do believe that the increased VCAM-1 (that is inflammation) may play a role, at least in part, in causing adverse remodelling.…”
Section: Discussionmentioning
confidence: 99%
“…[27] Tirofiban is a competitive inhibitor of GPIIb/IIIa receptors, [28] and it has been suggested that it has protective effects on the endothelium, acute coronary syndrome, and symptomatic coronary artery disease. [29,30] Warnholtz et al [31] reported improvement in the flow-mediated dilation of the brachial artery after PCI with tirofiban treatment. However, these studies were all performed in clinical settings where there was obvious endothelial damage, and the vascular effects of tirofiban on an intact endothelium is uncertain.…”
Section: Discussionmentioning
confidence: 99%
“…In ACS patients GP IIb-IIIa antagonists are administrated after distraction of the atherosclerotic plaque and in PCI treated patients (at least in those who undergo elective PCI) before the traumatic injury of the vessel caused by angioplasty procedure. However, contradictory to this hypothesis the third GP IIb-IIIa blocker tirofiban was reported to decrease the level of inflammatory markers in ACS [20][21][22] but not in patients undergoing elective PCI [19]. The clarification of this controversy needs further investigation and probably the direct comparison of the anti-inflammatory effects of different GP IIb-IIIa antagonists.…”
Section: Discussionmentioning
confidence: 99%
“…However, this antagonist did not affect CRP and IL6 plasma concentrations in patients with ACS [18]. Another GP IIb-IIIa antagonist, tirofiban, failed to decrease CRP, TNFa and IL6 in patients undergoing PCI [19] but suppress increase of CRP [20], IL6 [21] and soluble cell adhesion molecules [21,22] in patients with ACS. One more GP IIb-IIIa blocker, eptifibatide, was reported to decrease CRP and other inflammatory markers in coronary angioplasty [23,24], but these results were not confirmed by other authors [25].…”
mentioning
confidence: 99%